Examines DLL3-targeted immune therapies in small-cell lung cancer and frames DLL3 as a lineage-linked, dynamic antigen influencing responses and resistance.
Key Takeaways
- Cancer Immunity and Immunotherapy DLL3-Directed Immune Redirection in Small-Cell Lung Cancer
- You have multiple emails registered with Frontiers: You don't have a Frontiers account ?
- You can register here Delta-like ligand 3 (DLL3)